Source of BNP and ANP
Both ANP and BNP are produced primarily in the atria under normal physiological conditions, but in heart failure, BNP production shifts predominantly to the ventricles. 1
Normal Physiological State
ANP (Atrial Natriuretic Peptide)
- Primary source: Cardiac atria
- Storage mechanism: Pre-stored in atrial granules, allowing immediate release when needed
- Release pattern: Readily available for rapid secretion in response to atrial stretch 1
BNP (B-type Natriuretic Peptide)
- Primary source: Cardiac atria (in healthy individuals)
- Storage mechanism: Limited storage capacity; requires de novo synthesis for substantial release
- Gene response: The BNP gene responds rapidly to stimulation despite limited pre-formed stores 1
Pathological State (Heart Failure)
In heart failure and other conditions causing cardiac stress, there is a critical shift in BNP production:
- Ventricular myocytes re-express fetal genes including both ANP and BNP in response to pressure or volume overload 1
- Most BNP is then released from the ventricles rather than the atria 1
- The atria contain the highest concentrations of both peptides in normal individuals, but this distribution shifts to ventricular predominance for BNP in heart failure 1
Clinical Implications
This physiological shift explains why:
- BNP levels rise more dramatically than ANP in heart failure, making BNP a superior biomarker 2
- BNP requires synthesis "on demand" through gene activation, while ANP can be released immediately from pre-formed stores
- The magnitude of BNP increase typically exceeds that of ANP in cardiovascular disease states 3
Important caveat: While both peptides originate from cardiac myocytes, CNP (C-type natriuretic peptide) has different sources—primarily vascular endothelium, central nervous system, and bone—and should not be confused with ANP or BNP when discussing cardiac biomarkers 2, 4.